| Ulcerative Colitis

Inflectra vs Skyrizi

Side-by-side clinical, coverage, and cost comparison for ulcerative colitis.

Deep comparison between: Inflectra vs Skyrizi with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsSkyrizi has a higher rate of injection site reactions vs Inflectra based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Skyrizi but not Inflectra, including UnitedHealthcare

Category

Inflectra

Skyrizi

At A Glance

RouteIV infusion

FrequencyEvery 6-8 weeks

ClassTNF-alpha antagonist

RouteSC injection

FrequencyEvery 8-12 weeks

ClassIL-23 antagonist

Indications

Ulcerative Colitis
Rheumatoid Arthritis
Ankylosing spondylitis
Arthritis, Psoriatic
Psoriasis vulgaris

Psoriasis vulgaris
Arthritis, Psoriatic
Crohn Disease
Ulcerative Colitis

Dosing

Crohn's Disease, Ulcerative Colitis 5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks; regimen applies to adult and pediatric patients >= 6 years.

Rheumatoid Arthritis 3 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks in combination with methotrexate; may increase up to 10 mg/kg every 8 weeks or as often as every 4 weeks for incomplete response.

Ankylosing spondylitis 5 mg/kg IV at 0, 2, and 6 weeks, then every 6 weeks.

Arthritis, Psoriatic, Psoriasis vulgaris 5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks.

Psoriasis vulgaris, Arthritis, Psoriatic 150 mg SC at Week 0, Week 4, and every 12 weeks thereafter.

Crohn Disease Induction: 600 mg IV infusion over at least 1 hour at Week 0, Week 4, and Week 8; maintenance: 180 mg or 360 mg SC at Week 12 and every 8 weeks thereafter.

Ulcerative Colitis Induction: 1,200 mg IV infusion over at least 2 hours at Week 0, Week 4, and Week 8; maintenance: 180 mg or 360 mg SC at Week 12 and every 8 weeks thereafter.

Contraindications

Doses >5 mg/kg in patients with moderate or severe heart failure
Previous severe hypersensitivity reaction to infliximab products, inactive ingredients of INFLECTRA, or any murine proteins (including anaphylaxis, hypotension, and serum sickness)

Previous serious hypersensitivity reaction to risankizumab-rzaa or any excipient

Drug Interactions

1225View drug interactions

378View drug interactions

Adverse Reactions

Most common (>10%) Infections (upper respiratory tract infection, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain

Serious Serious infections (pneumonia, cellulitis, abscess, sepsis, tuberculosis, opportunistic infections), malignancies, lymphoma, hepatotoxicity (acute liver failure, autoimmune hepatitis), severe infusion reactions, lupus-like syndrome

Postmarketing Agranulocytosis, neutropenia, interstitial lung disease, Stevens-Johnson Syndrome, toxic epidermal necrolysis, peripheral demyelinating disorders (Guillain-Barre syndrome), acute liver failure, anaphylactic shock, cerebrovascular accidents, leukemia, melanoma, Merkel cell carcinoma

Most common Upper respiratory infections, headache, fatigue, injection site reactions, tinea infections, arthralgia, pyrexia, rash

Serious Cellulitis, osteomyelitis, sepsis, herpes zoster, pneumonia

Postmarketing Eczema, rash

Pharmacology

Infliximab-dyyb is a chimeric IgG1kappa monoclonal antibody TNF-alpha antagonist that neutralizes the biological activity of TNFalpha by binding with high affinity to soluble and transmembrane forms of TNFalpha, inhibiting receptor binding and downstream proinflammatory cytokine activity in RA, CD, UC, AS, PsA, and Ps.

Risankizumab-rzaa is a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine, inhibiting its interaction with the IL-23 receptor and suppressing the release of pro-inflammatory cytokines and chemokines.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Inflectra